Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Endocrinology > Pituitary > Flashcards

Pituitary Flashcards

1
Q

Adjuctive therapy in patients with persistent acromegaly.
1. Preferred first line?
2. second line? MOA? Monitoring caveat?
3. more refractory/challenging disease

A
  1. first-gen SS receptor ligands, octreotide and lanreotide. Increase to max tolerated dose to achieve IGF-1.
  2. Pegvisomant. MOA - competes with endogenous GH for binding at its receptor and blocks peripheral IGF1 production. Therefore, cannot monitor GH.
  3. Pasireotide (AE of glycemic disturbance)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Best management of persistent acromegaly after surgery for the following indications:
1. most RAPID response for tumor shrinkage and biochemical control.
2. Common AE?
3. Besides acromegaly, what other disease can it be used for?

A
  1. PASIREOTIDE ( somatostatin receptor ligand); it normalizes IGF-1 and may result in tumor shrinkage. Pegvisomant does not control tumor growth.
  2. Common AE is HYPERGLYCEMIA.
  3. Can also be used for Cushing disease (it decreases cortisol and ACTH)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
  1. Treatment for all forms of endogenous Cushing syndrome?
  2. MOA?
  3. What levels actually rise during treatment?
A
  1. MIFEPRISTONE
  2. glucocorticoid receptor blocker
  3. cortisol and ACTH
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MOA of somatostatin/SS analog

A

inhibits both GH and TSH. Therefore, can use in acromegaly and TSH secreting tumors. Can also reduce tumor size.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

After TSS for acromegaly, a fasting GH concentration [ ] suggests a complete remission even without the requirement for an oral glucose tolerance test

A

less than 0.4 ng/ml

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Isolated ACTH deficiency
1. most common cause

A
  1. prolonged exogenous glucocorticoid therapy. An isolated ACTH deficiency is extremely rare, except in hypophysitis associated with immune checkpoint inhibitors.

for glucocorticoid induced secondary AI, recovery of HPA axis can be reevaluated after glucocorticoid is stopped. Monitor with early morning serum cortisol and ACTH. A rise in ACTH is the first sign of axis recovery.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Patients with symptoms of AI and a morning serum cortisol in the range 3 and 15 ug/dl require what form of dynamic testing?

A

cosyntropin stim test or an insulin tolerance test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q
  1. What is the most common origin of clinically nonfunctioning pituitary adenomas
  2. what immunohistochemical positivity do they demonstrate?
  3. what transcription factor is expressed?
  4. if tumor growh recurrence occurs, what is the next best step?
A
  1. gonadotrope
  2. FSH and/or LH (stain for BETA subunits)
  3. Steroidogenic factor 1 (SF-1)
  4. Radiation therapy. Stereotactic radiotherapy is the best choice.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q
  1. Anticonvulsant drugs that lead to a false positive dex suppression test
  2. MOA?
  3. alternative testing for Cushings?
A
  1. carbamazepine, phenytoin, phenobarbital
  2. these drugs induce CYP3A4 enzyme, leading to increased dexamethasone metabolism. Always measure dex level simultaneously.
  3. late night salivary cortisol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are sources of a FALSE-POSITIVE dexamethasone suppression test?

A
  1. use of anticonvulsant drugs (carbamazepine, phenytoin, phenobarbital) “car pheny phen”
  2. oral estrogen
  3. rifampin
  4. pioglitazone

Test with 24 hour urine free cortisol or late night salivary cortisol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

DDx for pituitary stalk thickening

A
  1. congenital
  2. inflammatory - hypophysitis, sarcoidosis, granulomatosis with polyangiitis
  3. neoplastic - Langerhans cell histiocytosis, geminoma, lymphoma, metastatic disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Langerhans cell histiocyctosis (LCH)
1. present in what patient demographic
2. classic presentation
2. what other organs are involved besides the pituitary?

A
  1. young males
  2. isolated central diabetes insipidus
  3. bones (in 60% of the cases). Therefore, get a skeletal survey if suspicious for LCH (safe and inexpensive) to obtain a confirmatory bone biopsy. In smokers, pulmonary involvement can be seen.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Macimorelin GH-stimulation test
1. what is macimorelin and what is it used for?
2. MOA?
3. normal test is?
3. pitfalls?

A
  1. a ghrelin agonist. Tests for GH deficiency.
  2. Stimulates GH secretion by acting directly on somatotroph cells.
  3. GH > 2.8 ng/ml
  4. in postradiation hypopoituitarism, if early in the disease, Macimorelin GH stim test may be falsely normal (since radiation can take > 5 years to cause problems).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the tests for GH defiency and cutoff values for a positive test?

A
  1. insulin tolerance test (gold standard). Peak GH < 5.
  2. Macimorelin stim test. Peak GH < 2.8. May not detect eary GH deficiency after radiation.
  3. Glucagon stim test. Peak GH < 3.0 (normal BMI) or < 1 (BMI greater than 30).
  4. GHRH + arginine test –> may not detect early GH deficiency after radiation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

IgG4-related hypophysitis
1. what is it?
2. characteristics?
3. responds to?
4. what demographic is mostly affected

A
  1. an immune-mediated disease, often systemic
  2. infiltration of IgG4-positive plasma cells and lymphocytes, and fibrosis that can affect any organ
  3. glucocorticoids
  4. old men
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Distinguish between a thyrotropinoma and THRB-related resistance to thyroid hormone:
1. SHBG
2. Serum alpha subunit
3. TRH stim test (absent/attenuated or exaggerated?)
4. pituitary MRI

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

metastasis to the sella commonly presents with?

A

central diabetes insipidus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

how does lymphocytic hypophysitis present?

A

AI and central DI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

how does neurosarcoidosis present?

A

central DI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

POU1F1 gene (a transcription factor)
1. important for the development of?

A
  1. Somatotroph, thyrotroph, and lactotroph lineages. Therefore, deficiencies in GH, TH, PRL occurs in a pathogenic variant of this gene.

“Puffy Tho grew milky breasts”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the most common cause of congenital combined pituitary hormone deficiency? (GH, TSH, LH, FSH)

A

PROP1

“Proper Tho grew fish legs”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Patients with pathogenic variants in TBX19 (TPIT) present with?

A

isolated ACTH deficiency (the TBX19 gene product is needed for differentiation of corticotroph cells)

(think of a boxer/pitbull with AI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

If 3 or more pituitary axes are deficient, is a stim test needed to assess for GH deficiency?

A

NO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q
  1. severe hyponatremia following pituitary surgery is usually due to?
  2. treatment of moderate to severe hyponatremia following pituitary surgery (most rapid normalization)?
  3. when is demeclocycline used?
A
  1. SIADH
  2. TOLVAPTAN (an oral vasopressin receptor antagonist); hypertonic saline can also be used, usually at a rate of 0.5 to 1.0 mL/kg body weight per hour
  3. for patients with CHRONIC, symptomatic hyponatremia, such as that associated with malignancy. It causes partial nephrogenic diabetes insipidus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Hint that a tumor is not actually a prolactinoma

A

a discrepancy in the size vs PRL level. Also if tumor is not shrinking but PRL is decreasing with D2 agonist (can be d/t stalk effect)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q
  1. GH may metabolize?
  2. In patients on oral estrogens, what to do with GH dose?
  3. GH therapy may affect glucose in what way?
A

1a. cortisol –> relative adrenal insufficiency (therefore, increase hydrocortisone dose)
1b. free T4 –> therefore increase levothyroxine dose.
2. increase GH dose to maintain a steady IGF-1 level (can consider switching to transdermal estrogen to bypass liver and first pass effect and reduce impact of estrogen on GH dose).
3. 3. May lead to hyperglycemia

27
Q
  1. what is the hook effect?
  2. next step?
A
  1. When the assay reads a low/normal/slightly elevated PRL level (instead of it being extremely high) due to a high analyte concentration.
  2. re-measure prolactin after dilution to rule out macroprolactinoma/hook effect
28
Q

Familial Isolated Pituitary Adenoma Syndrome (FIPA)
1. clinica features?
2. method of inheritance
3. gene affected

A
  1. early onset acromegaly and a large pituitary tumor
  2. autosomal dominant
  3. aryl hydrocarbon receptor interacting protein (AIP), likely a tumor suppressor gene. “Second hit” hypothesis. Each of an affected patient’s children has a 50% chance of having inherited the pathogenic variant
29
Q

Diagnosis of acromegaly
1. what test is the gold standard? GH cutoff?
2. Once acromegaly is diagnosed, what is the next step?
3. If the previous study is unrevealing, then?

A
  1. The oral glucose suppression test. GH cutoff 0.4-1 ng/ml depending on the guideline
  2. Obtain a pituitary MRI
  3. obtain a GHRH level (to look for the presence of a GHRH-secreting neuroendocrine tumor elsewhere in the body)

**in ESRD, GH may fail to suppress

30
Q

The co-occurrence of suprasellar and pineal lesions is highly suggestive of?

A

a germinoma

31
Q

best test to screen for Cushing syndrome in pregnancy?

A

Salivary cortisol. Urine free cortisol increases in pregnancy

32
Q

for Cushing disease,
1. when an obvious pituitary adenoma (>/= 6 mm) is seen on imaging, what is the best next step in management?
2. when an adenoma is smaller or not obviously visible? What gradient indicates that ACTH secretion is pituitary-dependent?

A
  1. refer to a pituitary surgeon
  2. IPSS. When a central-to-peripheral ACTH gradient is > 2 at baseline and > 3 after CRH or desmopressin injection.
33
Q

Histochemical markers for the following lineages:
1. gonadotroph (FSH/LH)
2. somatotroph/lactotroph/thyrotroph (GH/PRL/TH)
3. corticotroph (ACTH)

A
  1. SF-1 (“SF is FSH/LH backwards”)
  2. Pit-1 (think of Tho who grew milky breasts in a big pit)
  3. Tpit
34
Q

In patients with prolactinomas, what are predictors of remission?

A

cabergoline x 2 yrs on 0.5 mg weekly (or 0.25 mg twice weekly), PRL 5.4 or less, max tumor diam of 3.1 mm

35
Q

Possible causes of hyperthyroxinemia with nonsuppressed TSH (8)

A
  1. Increased TBG (oral estrogen or pregnancy)
  2. lab assay interference (rule out second)
  3. thyroxine replacement therapy (including poor adherence)
  4. medications (rule out first)
  5. nonthyroidal illness
  6. TSH secreting pituitary adenoma
  7. resistance to thyroid hormone
  8. disorders of thyroid hormone transport or metabolism
36
Q

How do the following lab assay interference confound TFT results?
1. heterophilic or antiiodothyronine antibodies; familial dysalbuminemic hyperthyroxinemia
2. heterophilic or human antianimal antibodies; Macro-TSH

A
  1. falsely elevated free thyroid hormones
  2. falsely nonsuppresed TSH
37
Q

Do you follow GH and IGF1 in pregnancy in a patient with acromegaly?

A

NO. Stop meds for acromegaly and monitor clinically (pituitary MRI w/o contrast for vision symptoms or worsening h/a).

38
Q

effects of carbamazepine/oxarbazepine (antiseizure meds) on:
1. dex suppression test
2. TFTs?
3. patient on DDAVP

A
  1. false positive dex suppression test due to CYP3A4 inducer
  2. low FT4 but normal TSH. Patient is clinically euthyroid
  3. watch for hyponatremia since carbamazepine can enhance desmopressin’s effects (increase sensitivity of the renal tubules to endogenous and exogenous vasopressin)
39
Q

What is the pattern of recovery of the HPA axis after successful surgery for Cushing disease?

A

order of recovery:
1. ACTH
2. cortisol ( > 15 is full recovery and ok to stop HC; 10-15 do cosyntropin stim test)
3. DHEAS (high only if Cushing’s disease recurs)

check early morning serum cortisol and ACTH (before the HC dose) every 8-12 weeks

40
Q

post TSS, what are the criteria for starting DDAVP in the first DI phase (3)?

A

significant polyuria (greater than 250 ml/hr), elevated serum sodium, pt can’t keep up with urine output
give DDAVP in single doses due to impending SIADH phase

remember: phase post TSS is: DI-SIADH-DI, but not always

41
Q

In a patient with a history of childhood-onset GHD, should reinitiating GH therapy be done in the following:
1. isolated GH deficiency and a normal pituitary MRI
2. GH deficiency and multiple hormone deficiencies, with structural lesions; those with proven genetic causes.

A
  1. need to do a GH stim test first. Reinitiation of therapy without a stim test is not appropriate
  2. a low IGF-1 level 1 at least 1 month off GH therapy is sufficient documentation of persistent GHD without additional provocative testing
42
Q

what is the most common pituitary deficit after radiation-induced pituitary damage?

A

GH deficiency

Particularly in males, GH deficiency can be present despite normal serum IGF-1 levels

43
Q

In severe or longstanding primary hypothyroidism, what can be seen on pituitary MRI?

A

pituitary hyperplasia due to thyrotoroph-cell hyperplasia.

Hyperprolactinemia can be seen due to TRH stimulation (TRH stimulates both TSH and PRL to be released). PRL will decrease after treatment of hypothyroidism.

44
Q

Carney complex:

  1. form of inheritance. Associated with what gene?
  2. clinical features?
A
  1. A.D.; protein kinase A type 1 alpha regulatory subunit gene (PRKAR1A)
  2. GH excess or acromegaly, Cushing syndrome due to primary pigmented nodular adrenocortical disease, and large-cell calcifying Sertoli-cell tumors in males. Thyroid nodules are also seen.
    neuroendocrine manifestation: pigmented lesions of the skin and mucosa, CARDIAC MYXOMAS
45
Q

What is the pituitary imaging finding in histiocytosis?

A

an enhancing posterior sellar mass

46
Q

treatment for very aggressive prolactinoma/pituitary carcinoma refractory to cabergoline/bromocriptine, surgery, and stereotactic radiosurgery?

A

temozolomide

47
Q

common cancers causing pituitary mets

A

breast, renal cell, lung;

when the pituitary mass is fast growing, think of mets

48
Q
  1. What are symptoms of GH deficiency?
  2. How to diagnose?
  3. cutoff value to diagnose GHD?
A
  1. change in body composition (increase in abdominal girth, change in well-being with fatigue and worsening cognitive function including short-term memory), lower bone density, and cardiovascular risk.
  2. glucagon-stimulation test
  3. Endo Society Guidelines: <1 ng/ml; Acromegaly consensus group: <0.4 ng/ml
49
Q
  1. somatostatin analogs (octreotide, lanreotide, and pasireotide) decrease?
  2. which of these worsen glucose tolerance?
A
  1. GH and IGF-1; therefore improve insulin resistance.
  2. PASIREOTIDE (decreases GLP-1 and glucose insulinotropic peptide)
50
Q

True or False: oral contraceptive use is safe in women with microadenomas and there is minimal risk of tumor enlargement

A

TRUE

51
Q
  1. True or False: More than 2/3 of children with idiopathic isolated GH deficiency diagnosed by conventional criteria have normal GH secretion as adults
  2. Before continuing GH treatment in these patients, what should be done?
A
  1. TRUE
  2. GH-stimulation test one month after stopping GH. If GH deficiency is documented to still be present, resume GH treatment at a lower dosage than that used in childhood
52
Q

Pregnant woman with a sellar mass. MRI shows contrast enhancement. Dx?

A

lymphocytic hypophysitis

53
Q

Patient with history of cancer and/or histiocytosis:

  1. MRI findings?
  2. associated clinical finding?
A
  1. hypOenhancing mass

2. diabetes insipidus

54
Q

pituitary adenomas:

1. typical MRI feature?

A
  1. hypOenhancing

rarely associted with diabetes insipidus

55
Q

cystic lesion on pituitary MRI. Ddx?

A

Rathke cyst

56
Q

mifepristone:

  1. MOA?
  2. used in the treatment of?
  3. what is NOT recommended measurements to be used for dosage adjustment during mifepristone treatment? How should dosage be adjusted?
A
  1. a glucocorticoid receptor blocker. Therefore, cortisol and ACTH levels may actually rise during treatment
  2. all forms of Cushing syndrome
  3. cortisol and ACTH.
    The dosage should be adjusted solely based on clinical parameters of the activity of Cushing syndrome while avoiding symptoms of adrenal insufficiency
57
Q

Tx of acromegaly:

  1. how often is lanreotide given?
  2. for pegvisomant to be considered as first-line therapy, how often is administration?
A
  1. monthly
  2. daily; this has the highest likelihood of normalizing IGF-1 level. Since it is a GH receptor antagonist, GH cannot be used to monitor tx efficacy.
58
Q

Women on oral estrogen require what change in GH replacement to normalize serum IGF-1 compared to women on transdermal estrogen or no estrogen?

A

A 2-3 times higher GH replacement.

Therefore, if a woman switches from oral to transdermal estrogen, GH dose should be decreased to one-half or one-third of the original dosage.

59
Q

What is one of the absolute contraindications to GH therapy?

A

an active malignancy

60
Q
  1. What is the gold standard for assessing GH reserve? What is the caveat?
A
  1. an insulin tolerance test. HOWEVER, caution in a patient with a history of cranial surgery because of concerns regarding possible seizure induction by hypoglycemia.
    - -> An alternative test is a GLUCAGON-STIMULATION TEST
61
Q

DDx for: acute onset hypopituitarism in adolescence or young adulthood

A

craniopharyngioma –> calcification within the lesion
OR
germinoma (germ-cell tumors) –> co-occurrence of suprasellar and pineal lesions

62
Q

most likely dx in a pregnant woman with diffuse pituitary enlargement

A

Pituitary hyperplasia
MRI without GAD (or noncon MRI), since this is what you would order in pregnancy, shows focal enhancement rather than diffuse enhancement with GAD.

63
Q

management of prolactinoma during pregnancy

A
  1. visual field testing (not routine for microprolactinoma)
  2. MRI without gad
    do not follow PRL since it increases during pregnancy
64
Q
  1. monomeric prolactin - size
  2. macroprolactin - size
  3. if suspicious for macroprolactin/falsely elevated prolactin, what is the next step?
A
  1. 23-kDa
  2. 150-kDa
  3. polyethylene glycol (PEG) - can determine % monomeric and macroprolactin

Endocrinology (8 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions